MedTrace Logo

Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

NCT04521452 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2020-08-20

No results posted yet for this study

Summary

The purpose of this study is to assess an inhibitory effect of Evogliptin on the progression of mild-to-moderate aortic stenosis in patients with T2DM and calcific aortic stenosis.

Conditions

  • CAVD

Interventions

DRUG

Evogliptin

Subjects will receive evogliptin 5 mg daily

Sponsors & Collaborators

  • REDNVIA Co., Ltd.

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2024-09-30
Completion
2024-09-30
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04521452 on ClinicalTrials.gov